DexCom, Inc. (DXCM) Free Cash Flow (FCF): $1.08B
The free cash flow (FCF) for DexCom, Inc. (DXCM) is $1.08B. It is above its 12-month average by 26.14% ($853.95M).
DXCM Free Cash Flow (FCF) Chart
DXCM Average Free Cash Flow (FCF) Chart
DXCM Current vs Average Free Cash Flow (FCF) Chart
DXCM Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$1.08B
FREE CASH FLOW (FCF) AVG TTM
$853.95M
FREE CASH FLOW (FCF) AVG 3Y
$631.13M
FREE CASH FLOW (FCF) AVG 5Y
$475.73M
FREE CASH FLOW (FCF) AVG 10Y
$280.65M
FREE CASH FLOW (FCF) AVG 15Y
$184.93M
FREE CASH FLOW (FCF) AVG 20Y
$131.69M
CURRENT VS TTM AVG
+26.14%
CURRENT VS 3Y AVG
+70.68%
CURRENT VS 5Y AVG
+126.43%
CURRENT VS 10Y AVG
+283.82%
CURRENT VS 15Y AVG
+482.50%
CURRENT VS 20Y AVG
+717.97%
FCF Analysis
Free Cash Flow (TTM)
$1.08B
FCF Yield
4.64%
Price/FCF
21.5
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
DexCom, Inc. Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for DexCom, Inc. (DXCM)?
- The free cash flow (FCF) for DXCM stock is $1.08B.
- What is the TTM average free cash flow (FCF) for DexCom, Inc. (DXCM)?
- The TTM average free cash flow (FCF) for DXCM stock is $853.95M.
- What is the 3Y average free cash flow (FCF) for DexCom, Inc. (DXCM)?
- The 3Y average free cash flow (FCF) for DXCM stock is $631.13M.
- What is the 5Y average free cash flow (FCF) for DexCom, Inc. (DXCM)?
- The 5Y average free cash flow (FCF) for DXCM stock is $475.73M.
- What is the 10Y average free cash flow (FCF) for DexCom, Inc. (DXCM)?
- The 10Y average free cash flow (FCF) for DXCM stock is $280.65M.
- What is the 15Y average free cash flow (FCF) for DexCom, Inc. (DXCM)?
- The 15Y average free cash flow (FCF) for DXCM stock is $184.93M.
- What is the 20Y average free cash flow (FCF) for DexCom, Inc. (DXCM)?
- The 20Y average free cash flow (FCF) for DXCM stock is $131.69M.
DexCom, Inc. Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $1.08B |
| 2024-12-31 | $630.70M |
| 2023-12-31 | $511.90M |
| 2022-12-31 | $304.70M |
| 2021-12-31 | $53.30M |
| 2020-12-31 | $276.60M |
| 2019-12-31 | $134.50M |
| 2018-12-31 | $56.10M |
| 2017-12-31 | $26.00M |
| 2016-12-31 | $500000.00 |
| 2015-12-31 | $15.70M |
| 2014-12-31 | $7.40M |
| 2013-12-31 | $-5.50M |
| 2012-12-31 | $-42.60M |
| 2011-12-31 | $-38.13M |
| 2010-12-31 | $-49.54M |
| 2009-12-31 | $-42.38M |
| 2008-12-31 | $-39.94M |
| 2007-12-31 | $-36.65M |
| 2006-12-31 | $-47.09M |
| 2005-12-31 | $-27.23M |
| 2004-12-31 | $-14.19M |
| 2003-12-31 | $-9.87M |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach